RT Book, Section
A1 Howland, Mary Ann
A2 Hoffman, Robert S.
A2 Howland, Mary Ann
A2 Lewin, Neal A.
A2 Nelson, Lewis S.
A2 Goldfrank, Lewis R.
SR Print(0)
ID 1108422176
T1 Antidotes in Depth
T2 Goldfrank's Toxicologic Emergencies, 10e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071801843
LK accessemergencymedicine.mhmedical.com/content.aspx?aid=1108422176
RD 2024/04/24
AB The  traditional  role  of  glucagon  was  to  reverse  life-threatening  hypoglycemia  in  patients  with  diabetes  unable  to  receive  dextrose  in  the  outpatient  setting.  However,  in  medical  toxicology,  glucagon  is  used  “off  label”  early  in  the  management  of  β-adrenergic  antagonist  and  calcium  channel  blocker  toxicity  to  increase  heart  rate,  contractility,  and  blood  pressure  by  increasing  myocardial  cyclic  adenosine  monophosphate  (cAMP)  via  a  non–β-adrenergic  receptor  mechanism  of  action.  The  use  of  glucagon  is  based  primarily  on  animal  studies  and  as  well  as  human  case  series  and  case  reports.  The  effects  of  glucagon  are  often  transient.